BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Daniel K. Spiegelman sold 1,989 shares of the company’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $91.96, for a total transaction of $182,908.44. Following the completion of the sale, the chief financial officer now directly owns 16,460 shares in the company, valued at approximately $1,513,661.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 90.00 on Tuesday. BioMarin Pharmaceutical Inc. has a 1-year low of $73.45 and a 1-year high of $102.49. The company’s market capitalization is $15.56 billion. The company has a 50 day moving average of $90.49 and a 200 day moving average of $88.80.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 23rd. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.15. The business had revenue of $300 million for the quarter, compared to the consensus estimate of $296.54 million. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. BioMarin Pharmaceutical’s quarterly revenue was up 31.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.39 earnings per share. On average, analysts predict that BioMarin Pharmaceutical Inc. will post ($0.95) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Your IP Address:

Several institutional investors have recently bought and sold shares of BMRN. Norges Bank acquired a new position in BioMarin Pharmaceutical during the fourth quarter worth about $83,952,000. CMH Wealth Management LLC purchased a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth $1,885,000. Thrivent Financial for Lutherans raised its position in shares of BioMarin Pharmaceutical by 10.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 127,655 shares of the company’s stock worth $10,574,000 after buying an additional 12,240 shares during the last quarter. Clough Capital Partners L P raised its position in shares of BioMarin Pharmaceutical by 52.2% in the fourth quarter. Clough Capital Partners L P now owns 97,709 shares of the company’s stock worth $8,094,000 after buying an additional 33,509 shares during the last quarter. Finally, Palo Alto Investors LLC raised its position in shares of BioMarin Pharmaceutical by 9.5% in the fourth quarter. Palo Alto Investors LLC now owns 1,960,219 shares of the company’s stock worth $162,385,000 after buying an additional 169,320 shares during the last quarter. Hedge funds and other institutional investors own 97.78% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. Gabelli assumed coverage on shares of BioMarin Pharmaceutical in a report on Sunday, December 25th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. set a $123.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Saturday, February 25th. Barclays PLC lowered shares of BioMarin Pharmaceutical from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $125.00 to $105.00 in a report on Tuesday, November 29th. Vetr lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $91.77 price objective on the stock. in a report on Monday, November 28th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Wednesday, December 28th. Nine investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. BioMarin Pharmaceutical presently has an average rating of “Buy” and an average target price of $110.49.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

5 Day Chart for NASDAQ:BMRN

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.